Clinical trials: ORR
Objective Response Rate (ORR)
Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma
TACE lays a theoretical foundation for synergistic enhancement in combination with PD-1/PD-L1 immunosuppressive agents by reducing tumor burden and peripheral blood treg, improving the immune status of patients, reducing immune…
- Trial name
- NCT05582109
- Testing
- Envafolimab, Lenvatinib Combined With TACE
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction…
- Trial name
- NCT01824459
- Testing
- S-1, Oxaliplatin, Cisplatin
- Where
- China
- Volunteers
- 576 people
- Sponsor
- Sun Yat-sen University